← Back to Clinical Trials
Recruiting NCT05454267

NCT05454267 Early Detection of Vaping-related Vascular Diseases

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05454267
Status Recruiting
Phase
Sponsor University of Miami
Condition Vaping
Study Type OBSERVATIONAL
Enrollment 90 participants
Start Date 2022-09-12
Primary Completion 2027-06-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 40 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 90 participants in total. It began in 2022-09-12 with a primary completion date of 2027-06-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to determine how vaping affects blood vessels, in particular if early damage occurs in the lung vessels.

Eligibility Criteria

Inclusion Criteria: Vapers Group: 1. Current electronic cigarette (EC) Puff Bar users defined as using EC either daily or occasionally in the past 30 days for at least 6 months, and with 5% nicotine concentration pods. 2. Adults aged 18-40 years Healthy Group: 1. Healthy never smokers, never vapers 2. Adults aged 18-40 years Exclusion Criteria: 1. Current or past smoking of tobacco cigarette (TC) or other tobacco/nicotine products (e.g., smokeless tobacco, Hookah) or marijuana will be excluded from the study. 2. Subjects with self-reported history of chronic health problems including asthma, chronic obstructive pulmonary disease (COPD), morbid obesity (BMI\>40 kg/m2), hypertension or diabetes 3. Pregnant or breastfeeding women

Contact & Investigator

Central Contact

Adam Wanner, MD

✉ awanner@med.miami.edu

📞 (305)243-2568

Principal Investigator

Adam Wanner, MD

PRINCIPAL INVESTIGATOR

University of Miami

Frequently Asked Questions

Who can join the NCT05454267 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 40 Years, studying Vaping. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05454267 currently recruiting?

Yes, NCT05454267 is actively recruiting participants. Contact the research team at awanner@med.miami.edu for enrollment information.

Where is the NCT05454267 trial being conducted?

This trial is being conducted at Miami, United States.

Who is sponsoring the NCT05454267 clinical trial?

NCT05454267 is sponsored by University of Miami. The principal investigator is Adam Wanner, MD at University of Miami. The trial plans to enroll 90 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology